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Summary
Considerable circumstantial evidence suggests that
A42 is the initiating molecule in Alzheimer’s disease
(AD) pathogenesis. However, the absolute require-
ment for A42 for amyloid deposition has never been
demonstrated in vivo. We have addressed this by de-
veloping transgenic models that express A1-40 or
A1-42 in the absence of human amyloid  protein
precursor (APP) overexpression. Mice expressing
high levels of A1-40 do not develop overt amyloid
pathology. In contrast, mice expressing lower levels
of A1-42 accumulate insoluble A1-42 and develop
compact amyloid plaques, congophilic amyloid angi-
opathy (CAA), and diffuse A deposits. When mice
expressing A1-42 are crossed with mutant APP
(Tg2576) mice, there is also a massive increase in am-
yloid deposition. These data establish that A1-42 is
essential for amyloid deposition in the parenchyma
and also in vessels.
Introduction
Overexpression of Alzheimer’s disease (AD)-linked mu-
tant human APP transgenes has been the most reliable
means of promoting deposition of Aβ in the brains of
transgenic mice. As they age, these mutant APP mice
develop robust amyloid pathology and other AD-like
features, including decreased synaptic density, reactive
gliosis, and some cognitive deficits. However, these
mutant APP mouse models show little evidence of
overt neuronal loss and neurofibrillary tangle (NFT)
pathology (Hardy and Selkoe, 2002; Price et al., 1998).
One potential problem with most of the widely studied
mutant APP mice is that the high level of overexpres-
sion of mutant human APP may confound the pheno-*Correspondence: mcgowan.eileen@mayo.edu (E.M.); golde.todd@
mayo.edu (T.G.)
4 These authors contributed equally to this work.type. Overexpression of APP results in overproduction
of APP fragments, which may have neuroprotective or
neurotoxic functions. For example, secreted APP gen-
erated by α-secretase (sAPPα) can be neuroprotective,
whereas the carboxyl terminal fragment generated by
β-secretase cleavage (CTFβ) and a caspase-cleaved
fragment of APP (C31) can be neurotoxic (Lu et al.,
2000; Mattson, 2004; Yankner et al., 1989). Moreover
APP and fragments such as the APP intracellular do-
main have signaling functions that may also contribute
to a phenotype (LaFerla, 2002). Consequently, mice that
overexpress individual Aβ peptides in the absence of
overexpression of APP allow testing of hypotheses re-
garding (1) the role of select Aβ species in the initiation
and propagation of amyloid deposition in vivo and (2)
the specific contribution of each Aβ peptide to the phe-
notype seen in AD mouse models.
Much of the data that support a pivotal role for Aβ42
in AD have come from the study of mutations in the
APP and presenilin genes that cause early-onset famil-
ial forms of AD (Selkoe, 1998). The vast majority of
these mutations selectively increase the relative levels
of Aβ42. However, even in typical late-onset AD there
is evidence that Aβ42, a minor Aβ species, usually rep-
resenting less then 20% of the total Aβ secreted, is both
the earliest form and the predominant species depos-
ited in the brain parenchyma (Golde et al., 2000). In
contrast, Aβ40, the major Aβ peptide secreted by cells,
appears to be the predominant species deposited in
the amyloid deposits in the cerebral vasculature (con-
gophillic angiopathy, CAA) (Gravina et al., 1995; Iwat-
subo et al., 1994). Transgenic mouse studies using mu-
tant APP and PS transgenes have provided some
insights into the effects that altering the ratio of Aβ40
and Aβ42 have on time to onset of deposition, type of
deposit (e.g., diffuse versus compact), and extent of
CAA (Borchelt et al., 1997; Herzig et al., 2004; Holcomb
et al., 1998). However, such studies have not definitively
identified which Aβ species are responsible for seeding
amyloid deposition in either the parenchyma or vascu-
lature.
To address this question, we have generated trans-
genic mice that express Aβ1-40 or Aβ1-42 without APP
overexpression. For these studies we used cDNAs that
express fusion proteins between the BRI protein, in-
volved in amyloid deposition in Familial British (FBD)
and Danish Dementia (FDD) and Aβ1-40 (BRI-Aβ40) or
Aβ1-42 (BRI-Aβ42) (Lewis et al., 2001; Vidal et al., 1999,
2000) (Figure 1A). We have previously shown that trans-
fection of BRI-Aβ cDNAs results in high-level expres-
sion and secretion of the encoded Aβ peptide through
proteolytic cleavage of the fusion protein at a furin
cleavage site immediately preceding Aβ (Lewis et al.,
2001). Efficient secretion of Aβ from the BRI fusion pro-
tein distinguishes this approach from studies using Aβ
minigene constructs that generate high levels of intra-
cellular Aβ and minimal secreted Aβ (LaFerla et al.,
1995). The BRI-Aβ transgenic mice we have generated
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fst in BRI-Aβ40, followed by BRI-Aβ42A, with BRI-
igure 1. Biochemical Analyses of Aβ Levels in BRI-Aβ Mice
A) Schematic of the BRI-Aβ fusion proteins. BRI-Aβ fusion con-
tructs were designed to take advantage of the BRI protein that is
leaved by furin or a furin-like protease near the COOH-terminus
o release a soluble 23 amino acid peptide in the wild-type protein.
β1-40 or Aβ1-42 was fused to the C terminus of the BRI protein
t the furin cleavage site. This cleavage releases Aβ into the lumen
r extracellular space, resulting in efficient secretion. (B) IP/MS
nalysis of Aβ isoforms in BRI-Aβ mice. The spectra from the BRI-
β42 lines had single peaks detected with a mass/charge ratio (m/z)
f 4515 corresponding to human Aβ1-42. In BRI-40 mice, one peak
as detected at m/z 4330 corresponding to human Aβ1-40. The
houlder of the 4330 peak corresponds to the Aβ40 sodium adduct
ons. Peaks corresponding to human Aβ1-38, Aβ1-40, and Aβ1-42
ere detected in extracts from Tg2576 and were absent in non-
ransgenic mice and BRI wild-type mice. (C) RIPA-soluble (RIPA)
nd (D) RIPA-insoluble formic acid extractable (FA) Aβ levels in
emibrains (n = 3–7 mice per age point per group) from BRI-Aβ
ice were quantified by Aβ sandwich ELISAs. FA Aβ42 increased
ramatically with age in the BRI-Aβ42 mice. There was no evidence
or accumulation of insoluble Aβ40 in the BRI-Aβ40 mice with age.rovide substantial evidence that Aβ1-42 but not Aβ1-
0 is sufficient to promote Aβ deposition in mice.
esults
eneration of BRI-A Transgenic Mice
he mouse prion promoter (MoPrp) (Borchelt et al.,
996) was used to drive BRI-Aβ40 and BRI-Aβ42 trans-
ene expression. Linearized constructs were injected
nto fertilized oocytes from B6C3F1 mice. Multiple BRI-
β42 and BRI-Aβ40 founders were generated and
aintained on a B6C3 background. Transgenic found-
rs were screened by plasma-sandwich ELISAs. Six of
he highest Aβ42-expressing founders, with plasma
β42 levels equivalent to or higher than Aβ42 levels in
ged-matched Tg2576 mice (Hsiao et al., 1996), were
elected for further breeding. Subsequently, the two
ines that had the highest level of expression were cho-
en for further study. One BRI-Aβ1-40 founder had
β40 plasma levels higher than levels seen in age-
atched Tg2576 mice (Kawarabayashi et al., 2001),
nd this line was also expanded.
Transgene expression and protein levels in the mice
ere determined by Northern blotting, in situ hybridiza-
ion, and Western analysis (see Figure S1 in the Supple-
ental Data available online). Included in this analysis
ere BRI wild-type mice expressing the wild-type BRI
rotein under control of the MoPrP promoter. The BRI-
β40 line expressed the transgene at w2- to 3-fold
igher levels than the BRI-Aβ42A mice. In all lines, BRI-
β mRNA was expressed in a pattern characteristic of
he MoPrP promoter (Borchelt et al., 1996); with highest
xpression in the cerebellar granule cells and hippo-
ampus, followed by the cortex, pons, thalamus, and
idbrain (Figures S1A and S1B). In the two highest ex-
ressing BRI-Aβ42 lines, BRI-Aβ42A and BRI-Aβ42B,
he fusion transgene was expressed at levels approxi-
ating endogenous mouse APP expression (BRI-
β42A) or at approximately half this level (BRI-Aβ42B).
ull-length BRI-Aβ proteins levels (w37 kDa) were high-
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193Aβ42B having the lowest protein levels (Figures S1D
and S1E). Processed Aβ species (4 kDa) were detected
in both the BRI-Aβ40 and BRI-Aβ42 transgenic mice by
immunoprecipitation Western blotting (Figure S1F).
Full-length BRI-Aβ40 or BRI-Aβ42 did not show sig-
nificant alterations with age (Figure S2). BRI-Aβ40 and
BRI-Aβ42 mice have a normal lifespan with no obvious
behavioral abnormalities.
Specific Expression of A Peptide Isoforms
in Transgenic Mice
Although 4 kDa Aβ species were detetected by Western
immunoprecipitation, MALDI-TOF mass spectrometry
(IP/MS) (Wang et al., 1996) was used to definitively
identify the specific Aβ isoforms in PBS extracts from
the brains of BRI-Aβ mice in comparison to Tg2576
(Figure 1B). The BRI-Aβ42 lines show single peaks cor-
responding to human Aβ1-42. The relative peak heights
between the two lines were consistent with other data
indicating that the BRI-Aβ42A mice had higher expres-
sion than line BRI-Aβ42B. In BRI-40 mice, a single peak
was detected that corresponded to human Aβ1-40.
Several peaks were detected in extracts from Tg2576
mice that corresponded to human Aβ1-38, Aβ1-40, and
Aβ1-42. No peaks were detected in the wild-type BRI
transgenic or nontransgenic mice.
BRI-A42 but Not BRI-A40 Mice Accumulate
Detergent-Insoluble A
Aβ peptides in the brains of BRI-Aβ42 and BRI-Aβ40
mice from 3 to 22 months of age were characterized by
Aβ sandwich ELISAs (Figures 1C and 1D). Brains from
Tg2576 mice were used as controls. RIPA-soluble Aβ1-
40 levels in 3-month-old BRI-Aβ1-40 mice (80–120 pm/g)
were w2- to 3-fold higher than levels of Aβ1-40 in
3-month-old Tg2576 mice (w40 pm/gm). No apprecia-
ble change in the level of RIPA-soluble Aβ1-40 was ob-
served up to 22 months of age, and there was no evi-
dence for Aβ accumulation in the RIPA-insoluble formic
acid extractable (FA) fraction. Levels of RIPA-soluble
Aβ1-42 in 3-month-old BRI-Aβ42A and BRI-Aβ42B
brains were w2- to 3- and w1- to 1.5-fold higher than
the Aβ1-42 levels in 3- to 6-month-old Tg2576 brains.
Both BRI-Aβ42 lines showed large increases in RIPA-
insoluble Aβ1-42 levels with age. In the oldest BRI-Aβ42
mice, the levels of RIPA-insoluble Aβ1-42 exceed the
Aβ1-42 levels seen in aged Tg2576 mice. Aβ42 and
Aβ40 could be readily detected in plasma from the BRI-
Aβ42 and BRI-Aβ40 mice, respectively (Figure S3). No
Aβ40 can be detected in plasma from BRI-Aβ42 mice,
and conversely, no Aβ42 was detected in plasma from
BRI-Aβ40 mice.
Extensive Vascular and Parenchymal Amyloid
Pathology in BRI-A42 but Not BRI-A40 Mice
The biochemical analysis indicated that BRI-Aβ42 mice
selectively accumulated detergent-insoluble Aβ as they
aged and that the BRI-Aβ40 mice did not. Immuno-
staining with anti-Aβ antibodies and thioflavin S stain-
ing showed that both lines of BRI-Aβ42 mice, but not
BRI-Aβ40 mice, developed compact amyloid depositsand diffuse Aβ deposits with age (Figure 2). In contrast
to other mutant APP transgenic mice (Hsiao et al., 1996;
Price et al., 1998), cerebellar Aβ accumulation was the
earliest and most consistent feature in both lines of
BRI-Aβ42 mice. In the BRI-Aβ42A mice, cored plaques
were observed as early as 3 months of age in the mo-
lecular layer, with diffuse Aβ deposition becoming more
prominent with age. Forebrain pathology occurred later
and was more variable; occasional extracellular plaques
were observed in the entorhinal/piriform cortices and
the hippocampus at 6 months of age, but were not con-
sistently present until at least 12 months in BRI-Aβ42A
mice. The oldest mice had more widespread patholo-
gy, developing thioflavin S-positive-cored and diffuse
plaques in the cerebellum, cortex, hippocampus, and
olfactory bulb, in a similar manner to pathology de-
scribed for Tg2576 (Figure S4). Onset of amyloid pa-
thology in the BRI-Aβ42B mice was more variable than
in the BRI-Aβ42A mice; by 20 months of age, these
mice had widespread cerebellar and forebrain pathol-
ogy with a similar plaque distribution to that seen in the
BRI-Aβ42A mice. The greatest amlyoid plaque burden
was detected with N-terminal antibodies such as Bam-
10 and 82E1 (Figures 2 and 4). Immunostaining with
Aβ40 or Aβ42 end-specific antibodies was consistent
with the notion that the deposited Aβ was almost en-
tirely composed of Aβ42 (Figure 2E). We could not rule
out that trace amounts of Aβ40, derived from endoge-
nous mouse APP, or limited proteolysis, were present
in the core of some large compact plaques. Despite
similar levels of BRI expression at the mRNA level,
there was no pathology apparent in the brains of BRI
wild-type mice at any age (up to 24 months; Figure 2L).
Congophilic amyloid angiopathy (CAA) was absent in
the BRI-Aβ40 mice, but was a prominent feature in the
BRI-Aβ42 mice (Figure 2K). EM analysis demonstrated
that the CAA was fibrillar and closely associated with
the basal lamina (Figures 3A and 3B), similar to CAA
observed in AD. EM analysis of extracellular amyloid
plaques showed dense amyloid cores with radiating fi-
brils (Figure 3C). Many bundles of dystrophic neurites
were also present at the periphery of the dense cored
extracellular plaques. Compact plaques were small rel-
ative to those seen in Tg2576 mice (mean plaque diam-
eter 38 ± 5 m at 3 months to 53 ± 3 m at 16–18
months of age). Reactive astrogliosis was associated
with the compact plaques (Figure 2J). There was little
evidence of tau pathology, with only rare CP13-positive
dystrophic neurites seen in association with the dense
cored plaques in the oldest mice.
To determine if endogenous mouse Aβ was present
in the deposits, a monoclonal antibody raised against
aggregated mouse Aβ42 (32.4.1) that specifically recog-
nizes an epitope in mouse Aβ1-16 and does not cross-
react with human Aβ by ELISA (data not shown) was
used to stain brain sections from human AD and BRI-
Aβ42 mice. This antibody did not detect plaques from
human AD tissue (Figures 4A and 4B). In BRI-Aβ42
mice, the antibody labeled a subset of the Aβ plaque
cores, particularly in the cerebellum, and some diffuse
plaques in older mice (Figures 4C and 4D). These data
indicate that endogenous mouse Aβ is present in the
plaques. We also immunostained sections from the
BRI-Aβ42 mice with an antibody specific for the N-ter-
Neuron
194Figure 2. Amyloid Pathology in BRI-Aβ Mice
Progression of amyloid deposition (total Aβ
immunostaining with 33.1.1 raised against
Aβ1-16) in the cerebellum of BRI-Aβ42A mice
at 3 months (A), 6 months (B), and 16.5
months (C). BRI-Aβ42 mice develop both dif-
fuse (arrow in [C]) and compact thioflavin
S-positive deposits (D). Plaques were immu-
noreactive with Aβ42 end-specific antibod-
ies (E). No pathology was evident even in
16.5-month-old BRI-Aβ40 mice, immuno-
stained with a panel of Aβ antibodies or
thioflavin S (F). Old (19 month) BRI-Aβ42
mice show widespread forebrain Aβ depos-
its, particularly in the molecular layer of the
hippocampus (G) and the entorhinal/piriform
cortex (H). The entorhinal Aβ deposits were
largely diffuse, and neurons were often ob-
served within these diffuse deposits (I). In-
creased gliosis was associated with plaque
deposition (J). Sections were immunostained
with anti-GFAP (brown reaction product) fol-
lowed by immunostaining for Aβ using the
antibody BAM-10 (black reaction product).
CAA was progressive and severe in old mice
(K); vessels were stained with thioflavin S. A
dense cored plaque is also visible. The vas-
cular deposits were fibrillar, as demon-
strated by electron microscopy (see Figure
3). (L) wild-type BRI mice had no amyloid pa-
thology (total Aβ immunohistochemistry) at
ages up to 24 months of age. Scale bars: 60
m (A–F), 200 m (G), 300 m (H), 20 m (I),
30 m (J).minal truncated and modified pyroglutamate Aβ spe- d
icies Aβ[N3pe]. A proportion of the cored plaques and,
to a lesser extent, the diffuse amyloid were immuno- o
apositive for Aβ[N3pe], showing that this N-terminal
modified pyroglutamate Aβ species was present in the n
Aplaques in the BRI-Aβ mice (Figures 4E and 4F).
m
aEnhanced Pathology in BRI-A42 × Tg2576
Bigenic Mice a
oHemizygous BRI-Aβ42A mice were crossed with hemi-
zygous APPsweTg2576 mice, and the amount of Aβ de- (
(position in the bigenic BRI-Aβ42/Tg2576 offspring, age-
matched singly transgenic BRI-Aβ42A, and Tg2576 and a
Anontransgenic littermates was analyzed by biochemical
and immunohistochemical methods. Amyloid deposi- t
Ation initially develops in the cerebellum of BRI-Aβ42
mice and is extensive by 12 months of age, whereas, A
mforebrain pathology only consistently develops after 12
months of age. In contrast, amyloid deposition in T
lTg2576 mice only occurs in the forebrain after 6 months
of age, and no cerebellar deposits are routinely ob- t
tserved. For this reason, we analyzed the hindbrain (in-
cluding cerebellum) and forebrain Aβ levels indepen- bently at 6, 10, and 14.5 months (Figure 5). Anti-Aβ
mmunohistochemsitry showed marked augmentation
f Aβ deposition throughout the cortex, hippocampus,
nd cerebellum. Representative sections of the entorhi-
al/piriform cortical areas from 14.5-month-old BRI-
β42A, Tg2576, and bigenic BRI-Aβ42/Tg2576 litter-
ate mice are shown in Figures 5A–5C. RIPA-soluble
nd RIPA-insoluble FA Aβ levels in both the forebrain
nd hindbrain were analyzed by Aβ ELISA. At 6 months
f age, the levels of RIPA-soluble Aβ in the forebrain
Figure S5A), hindbrain (data not shown), and plasma
Figure S5B) of the crossed mice were consistent with
n additive effect of the two transgenes with respect to
β production, providing assurance that alteration in
ransgene expression would not confound these studies.
marked increase in both RIPA-insoluble FA extracted
β40 and Aβ42 was seen in the forebrain of bigenic
ice compared to single transgenic BRI-Aβ42 or
g2576 littermates (Figure 5D). The increase in FA Aβ
evels was greater than that expected for a simple addi-
ive effect of Aβ levels in BRI-Aβ42 and Tg2576 (w30-
o 40-fold increase at 10 months of age in the fore-
rain). Additionally, although Aβ deposition does not
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195Figure 3. Electron Microscopy of Congo-
philic Amyloid Angiopathy and Aβ Plaques in
BRI-Aβ42 Mice
CAA was pronounced in BRI-Aβ42 mice. (A)
Amyloid deposit (amy) at the outer basal
lamina (marked with *) of an arteriole found
at the cortical surface. An interendothelial
junction is indicated by the double arrow-
head. The boxed area in (A) is enlarged in
(B). (B) Note the disruption of basal lamina
(bl) between the astrocyte (ast) and smooth
muscle cells (smc) by bundles of amyloid fi-
brils (amy). Arrowhead points to surface ves-
icles of SMC. Many of the extracellular amy-
loid plaques in the BRI-Aβ mice had dense
amlyoid aggregates with radiating fibrils (C).
There were many dystrophic neurites (arrow-
heads) present at the periphery of these
plaques. vl, lumen; e, endothelium; SMC,
smooth muscle cell; Ast, astrocytes. Scale
bars: 1 m (A), 30 nm (B), and 5 m (C).occur in the cerebellum of Tg2576, Aβ40 and Aβ42
levels were substantially elevated in the hindbrain of
the bigenic mice compared to the single transgenic lit-
termates (Figure 5E). Taken together these data sug-
gest that Aβ42, by itself, accelerates amyloid deposi-
tion in the Tg2576 mice.
Discussion
We have developed transgenic mice expressing BRI-
Aβ40 or BRI-Aβ42 fusion proteins. Biochemical analy-
ses of these mice demonstrate that these transgenes
selectively express the encoded Aβ peptide in vivo.
Since there is no pathological phenotype in mice over-
expressing the BRI wild-type protein under control of
the MoPrP, any resultant phenotype is likely to be at-
tributed to the specific Aβ peptide expressed. BRI-
Aβ40 mice express 2- to 3-fold higher levels of Aβ1-40
than Tg2576 mice, but do not develop Aβ deposits by
24 months of age. In contrast, the BRI-Aβ42 lines,
which have w5- to 10-fold lower transgene expression
than BRI-Aβ40 mice, develop robust parenchymal and
cerberovascular Aβ deposits as early as 3 months of
age. Reactive gliosis was observed in the BRI-Aβ42
mice, but the mice had neither obvious neuronal cell
loss nor prominent neurofibrillary pathology. The lack
of a more robust AD-like phenotype in the BRI-Aβ42
mice suggests that the absence of a more prominent
AD phenotype in mutant APP mice cannot be attributed
to protection conferred by overexpression of other APP
derivatives (e.g., sAPPα) (Mattson, 2004), although this
can only be definitely tested by crossing the BRI-Aβ42
mice into an APP knockout background. Bigenic BRI-
Aβ42/Tg2576 mice show a marked increase in the ex-
tent of Aβ deposition and validate the physiologic rele-
vance of selectively increasing Aβ42 via the BRI fusion
proteins. Such data are entirely consistent with the in-
creases in deposition produced by APP and PS mutant
transgenes that shift γ-secretase cleavage to augmentAβ42 production and accelerate Aβ deposition (Borchelt
et al., 1997; Holcomb et al., 1998).
The pattern of amyloid deposition in BRI-Aβ42 mice
generally followed the expression pattern of the PrP
transgene (Borchelt et al., 1996) and was similar to
Tg2576 pathology except for the presence of a large
number of plaques in the cerebellum of BRI-Aβ42 mice.
The extensive Aβ42 deposition in the cerebellum and
severe CAA in the BRI-Aβ42 mice mimics the pattern of
amyloid deposition seen in FBD (Ghiso et al., 2000; Hol-
ton et al., 2001; Vidal et al., 1999). Though high levels
of transgene expression are seen in the cerebellum of
both Tg2576 and BRI-Aβ42 mice, we do find that the
level of RIPA-soluble Aβ in the nondepositing Tg2576
forebrain is w50% higher than that found in the hind-
brain and that BRI-Aβ42 mice generate significantly
higher Aβ levels in their hindbrain compared to Tg2576
mice. This may indicate that the level of enzymatic pro-
cessing of BRI-Aβ42 and APP varies in different brain
regions and might in turn partially account for the differ-
ence in the distribution of amlyoid deposition in Tg2576
and BRI-Aβ42 mice and between AD and FBD. How-
ever, the data from the BRI mice are potentially con-
founded by the fact that cerebellar Aβ deposits are
present by 3 months of age, preventing us from defini-
tively establishing steady-state Aβ levels prior to depo-
sition.
As has been reported from biochemical data in one
APP transgenic line (Pype et al., 2003), we find immuno-
histochemical evidence for codeposition of mouse Aβ
within a subset of plaques. Such data are not surprising
given that in vitro data demonstrate that human and
mouse Aβ can coassemble into aggregates (Fung et al.,
2004). We also find evidence for truncation and modifica-
tion of the deposited Aβ; a subset of plaques are labeled
by an antibody recognizing Aβ[N3pe]. The most promi-
nent staining with this antibody was seen in the com-
pact cerebellar plaques of old (18 month) BRI-Aβ42
mice. Since the cerebellum is the initial site of deposi-
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Figure 4. Mouse Aβ and Modified Aβ Peptides Are Present in the t
Plaques of BRI-Aβ42 Mice c
(A) Senile plaques in the temporal gyrus from an AD brain, Braak r
stage VI, immunostained with anti-Aβ1-16 (33.1.1). (B) A serial sec- a
tion of the AD tissue in (A) immunostained with anti-rodent Aβ that E
does not detect human Aβ deposited in AD. (C) Total Aβ immuno- tstaining using antibody 33.1.1, in the cerebellum of a 17-month-old
lBRI-Aβ mouse shows multiple cored plaques, a subset of these
Aplaque cores are immunopositive for rodent Aβ in a serial section
a(D). Arrows in (C) and (D) indicate the same plaques immunostained
with 33.1.1 and rodent Aβ, respectively. (E) Diffuse and dense cored
plaques in the cerebellum were immunopositive with an anti-Aβ1- t
16 (82E1, IBL), a subset of these plaques were stained by an anti- e
body that recognizes a truncated N-terminal modified pyrogluta-
Amate form of Aβ (N3pE Aβ) (F). Arrows in (E) and (F) indicate the
tsame plaques immunostained with anti-Aβ1-16 and anti-N3pE Aβ,
1respectively. Scale bars: 200 m (A–D) and 60 m (E and F).
A
H
tion in these mice, such data would be consistent with o
postdeposition modification of the deposited Aβ. t
A comparison of the various transgenic models of Aβ o
deposition reveals that there is a great deal of variability A
with respect to the age at which deposition begins, the o
nature and composition of the Aβ deposits (compact e
versus diffuse; proportion of Aβ40 versus Aβ42), and p
the extent of CAA (Borchelt et al., 1997; Chishti et al.,
2001; Games et al., 1995; Herzig et al., 2004; Holcomb h
et al., 1998; Hsiao et al., 1996; Mucke et al., 2000; p
Sturchler-Pierrat et al., 1997). One factor that clearly 1
regulates Aβ deposition is the relative levels of Aβ42, o
which can be manipulated by either expressing APP a
ttransgenes with FAD-linked mutations (e.g., APP V717I/Futations) or with coexpression of mutant presenilin
ransgenes that shift γ-secretase cleavage to favor in-
reased production of Aβ42. Increasing relative Aβ42
evels lowers the age when deposition first occurs, in-
reases the amount of diffuse Aβ, and promotes paren-
hymal versus cerebrovascular deposition. In contrast,
high ratio of Aβ40 to Aβ42 was associated with severe
AA in the absence of parenchymal amyloid (Herzig et
l., 2004). However, because these mutations have
ther physiological effects, it was possible that other
lterations in function contributed to the phenotype.
ur data critically extend these observations and pro-
ide unequivocal in vivo evidence that, in the absence
f mutations within the Aβ sequence, Aβ42 expression
ppears to be necessary for both parenchymal and
erebrovascular amyloid deposition. Thus, although the
β40/Aβ42 ratio influences the extent of vascular ver-
us parenchymal deposition, Aβ42 appears to be re-
uired to “seed” both types of deposits.
In vitro biophysical studies of synthetic Aβ demon-
trate that Aβ42 aggregates more readily than Aβ40,
resumably because Aβ42 nucleates more efficiently.
ollowing nucleation, there seems to be little kinetic or
hermodynamic differences between elongation of fi-
rils composed of either Aβ40 or Aβ42 (Hasegawa et
l., 1999; Jarrett et al., 1993; Jarrett and Lansbury,
993). Although numerous trans-acting factors such as
poE (Bales et al., 1999; Holtzman et al., 2000) and Aβ
egrading enzymes can modulate Aβ deposition (Farris
t al., 2003; Ohno et al., 2004), alterations in these fac-
ors do not result in complete reversal of the deposition
henotype. Thus, the simplest explanation for the com-
lete lack of pathology in the BRI-Aβ40 mice would be
he relative inability of Aβ40 to initiate nucleation events
apable of promoting amyloid deposition. Similar in vivo
esults have been obtained in a Drosophila model using
different fusion protein strategy (Iijima et al., 2004).
xpression of Aβ1-42, but not Aβ1-40, promoted pep-
ide accumulation of diffuse intracellular and extracellu-
ar deposits in the transgenic flies. Significantly, such
β42 accumulation was associated with neurodegener-
tion.
These findings raise an important question regarding
he possible role of intracellular Aβ in Alzheimer’s dis-
ase. Previous studies with transgenic mice expressing
β minigenes that are not efficiently secreted suggest
hat intracellular Aβ can be neurotoxic (LaFerla et al.,
995), as do studies of direct injection of aggregated
β into cultured primary neurons (Zhang et al., 2002).
owever, none of these studies prove or disprove a role
f intracellular Aβ in AD pathogenesis. The BRI-Aβ mice
hat we have developed are clearly distinct from these
ther “minigene” models in that they efficiently secrete
β. To date we have little evidence for accumulation
f intracellular Aβ in these mice; thus, they provide an
xcellent tool to study the effects of secreted Aβ inde-
endently of APP transgenes.
Collectively our data provide further support for the
ypothesis that Aβ42 is the initiating molecule in the
athogenesis of AD (Hardy and Selkoe, 2002; Younkin,
998). These data provide definitive in vivo confirmation
f predictions inferred from (1) in vitro studies of Aβ
ggregation, (2) effects of PS and certain APP muta-
ions on Aβ production and deposition, and (3) analyses
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197Figure 5. Enhanced Pathology in BRI-Aβ42 × Tg2576 Bigenic Mice
Transgenic mice expressing both BRI-Aβ42 and mutant APPswe (Tg2576) have enhanced senile plaque pathology in the forebrain compared
with their singly transgenic littermates and significantly elevated insoluble Aβ levels in the forebrain and hindbrain. Entorhinal/piriform cortex
of 14.5-month-old BRI-Aβ42A mouse (A), 14.5-month-old Tg2576 (B), 14.5-month-old BRI-Aβ42 × Tg2576 bigenic mouse (C) immunostained
with anti-total Aβ (33.1.1). All mice were littermates. FA Aβ levels in the forebrain (D) and hindbrain (E) of an aging series of bigenic BRI-Aβ/
Tg2576 compared with their single transgenic littermates. Scale bars: 300 m (A–C).of Aβ peptides in the human AD brain (Gravina et al.,
1995; Iwatsubo et al., 1994). Although our studies show
that Aβ42 is necessary to initiate aggregation of Aβ,
they do not demonstrate that aggregation of Aβ42, by
itself, is sufficient to induce all the hallmark pathologies
of AD in mice, including neurofibrillary tangles and cell
loss. This may reflect a simple limitation of the mouse
models that we and others employ, or could point to
some more complex aggregation phenomena that may
require interaction of Aβ42 with Aβ40 or other Aβ spe-
cies to drive AD pathogenesis. In any case, the BRI-Aβ
transgenic mice that we have developed provide mod-
els for further studies of the potential physiologic and
pathologic roles of Aβ40 and Aβ42 in vivo.
Experimental Procedures
Generation of Transgenic Mice
The BRI-Aβ40, BRI-Aβ42 fusion constructs (Lewis et al., 2001), or
BRI wild-type constructs were subcloned into the MoPrP/blue-
script vector (Borchelt et al., 1996) at the XhoI restriction site. The
transgene was linearized by NotI restriction digest, gel purified, and
digested with β-agarase according to the manufacturer’s condi-
tions (New England Biolabs). The linearized construct was injected
into the pronuclei of single-cell embryos from C3B6F1 × B6 mice
and implanted into pseudopregnant females. Founder pups wereidentified by PCR for the fusion construct or wild-type construct
against an internal PS2 control PCR. Founder mice were back-
crossed to C3B6F1 mice, and the transgenic lines were maintained
on a C3B6 hybrid strain. All animal procedures were conducted
with Mayo Clinic’s animal care and use committee approval.
Bigenic BRI-A42 x Tg2576 Mice
Hemizygous BRI-Aβ42A mice were mated with Tg2576 mice ex-
pressing mutant APPswe under control of the hamster prion pro-
moter (Hsiao et al., 1996), generating bigenic BRI-Aβ42/Tg2576,
BRI-Aβ42, Tg2576, and nontransgenic offspring. Tg2576 mice were
maintained on a B6/SJL background. For all studies, age- and
strain-matched littermates were used.
In Situ Hybridization
Sagital cryostat sections (15 m) were fixed in 4% paraformalde-
hyde, dehydrated, and hybridized with a transgene-specific oligo-
mer (5#-ACACAGTCGATAAATAAAGAAACCCAGGTGATCAATG-3#)
3#-end labeled with α35S dATP. Sections were hybridized at 37°C
overnight in buffer containing 4× SSC, 1× Denhardt’s solution, 50%
v/v deionized formamide, 10% w/v dextran sulfate, 200 mg/l her-
ring sperm DNA, and 0.03% β-mercaptoethanol. Control sections
were hybridized in the presence of a 50- to 100-fold molar excess
of unlabeled oligonucleotide. After hybridization, the sections were
stringently washed (1× SSC at 50°C), dehydrated, and exposed to
β max hyperfilm (Amersham) for 7–10 days.
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198Northern Blotting 2
vTotal RNA was extracted from the brains of male and female BRI-
Aβ mice using TRIzol reagent (Invitrogen) according to the manu- 1
afacturer’s instructions. Nontransgenic and mutant BRI transgenic
mice were used as controls. Total RNA (15 g) was run on a MOPS- t
(formaldehyde denaturing gel and transferred to nitrocellulose
membranes by capillary action. The blot was probed with a 32P- g
radiolabeled oligonucleotide probe specific for both mouse and hu-
man BRI, stripped, and reprobed with a 32P-radiolabeled APP E
BcDNA probe and subsequently with a 32P-radiolabeled histone
probe. Band densities were quantified using phosphorimage d
rscreens (Kodak) and Imagequant software (Molecular Dynamics).
o
aWestern Analysis
8Proteins were extracted from brain tissues by sonication in a 2%
pSDS/1% protease inhibitor cocktail solution. The resulting homog-
enate was centrifuged at 100,000 × g for 1 hr at 4°C. The superna-
tant containing the SDS-soluble fraction was aliquoted and stored
Sat −80°C. Total protein concentrations were determined using the
T“BCA Protein Assay kit” (Pierce). Protein extracts from BRI-Aβ mice
wwere run on a SDS denaturing gel and transferred to Immobilon P
membranes. Tg2576 and wild-type BRI transgenic lines were in-
Acluded as controls. Blots were probed with monoclonal antibodies
to human Aβ (6E10 and BAM10) followed by anti-mouse HRP or
Tanti-rabbit HRP conjugated secondary antibody, respectively. Blots
twere stripped and reprobed with anti-β-actin or α-tubulin as a load-
cing control.
f
NImmunoprecipitation Western Analysis
sBrain samples were homogenized in 2% SDS and diluted in RIPA
Mbuffer. Protein G was added and the sample mixed at 4°C for 1 hr
wprior to centrifugation for 60 s at 13000 rpm. The rabbit polycolonal
Aβ antibody, 3160, with Protein G (Pierce) was used to immuno-
precipitate the Aβ peptide at 4°C overnight. Then samples were R
centrifuged and the supernatants run on SDS denaturing gels (Bio- R
rad) and transferred to 0.2 m nitrocellose membranes. Blots were A
boiled for 10 min in 0.1 M PBS and probed with the monoclonal P
anti-Aβ, 6E10, followed by anti-mouse HRP. Tg2576 and nontrans-
genic samples and Aβ peptides were run as controls. R
BMass Spectrometry
JSix-month-old brains from the BRI-Aβ42, BRI-Aβ40, Tg2567, wild-
(type BRI lines, and nontransgenic littermates were homogenized in
APBS plus protease inhibitor solution to extract soluble proteins.
NHuman Aβ peptides were isolated by immunoprecipitation using
two monoclonal anti-Aβ antibodies (6E10 and 4G8) and analyzed B
by a MALDI-TOF mass spectrometry (Wang et al., 1996). s
P
A Sandwich ELISAs b
Mouse hemibrains (excluding the olfactory bulb) for BRI-Aβ40 and B
BRI-Aβ42 studies or forebrain and hindbrain for BRI-Aβ42 × Tg2576 J
studies were homogenized in RIPA buffer and ultracentrifuged to A
separate RIPA-soluble and -insoluble fractions. The insoluble pro- c
teins were extracted using 70% formic acid. Formic acid samples N
were neutralized with Tris base buffer, and all samples were appro-
C
priately diluted (from 10- to 5000-fold). For plasma analysis of Aβ,
s
blood samples were centrifuged at 3000 rpm for 10 min at 4°C
E
and the plasma decanted and diluted appropriately. Aβ levels were
m
determined by end-specific sandwich ELISAs (Kawarabayashi et
6
al., 2001) using Ab9 (anti Aβ1-16 of Aβ) as the capture antibody and
F21.3.1 (anti Aβ 35-42) or 13.1.1 (anti Aβ 35-40) as the detection
Fantibodies for Aβ42 and Aβ40, respectively (n = 3–7 mice per age
Spoint per group). Nontransgenic mice (n = 13) and Tg2576 mice at
a3, 6, 12 and 18 months (n = 3 at each time point) were included on
ceach ELISA plate as controls.
F
tImmunohistochemistry
1Paraffin-embedded tissue sections (5 m) from BRI-Aβ40, BRI-
Aβ42, and wild-type BRI mice (3–22 months of age, minimum of n = G
B3 per age group) were immunostained with Aβ antibodies, including
anti-total Aβ (Bam 10, 1:50,000, Sigma; 6E10, 1:10,000, Signet; a
e33.1.1, 1:1,000; T. Golde; 82E1, 1:1000, IBL), anti-Aβ40 (13.1.1.,
1:1,000, T. Golde), anti-Aβ42 (21.3.1., 1:1,000, T. Golde), 4G8 (Aβ17- 54; 1:5,000, Signet), anti-Aβ[n3pE] (8E1, 3rd N-terminal residue con-
erted to pyroglutamate, 1:1000, IBL), and anti-rodent Aβ (32.4.1.
:1000, C. Eckman/T. Golde) on a DAKO autostainer using standard
vidin or streptavidin biotin peroxidase methods. Additional sec-
ions were immunostained with thioflavin S, anti-tau antibodies
CP13, 1:100, P. Davies), and glial markers (GFAP, 1:100, Bio-
enex).
lectron Microscopy
RI-Aβ mice were perfused with saline followed by 2.5% glutaral-
ehyde/2% paraformaldehyde/0.1 M cacodylate buffer. The ento-
hinal cortex was removed, cut into 2 mm3 pieces, postfixed in 1%
smium tetroxide and 1% uranyl acetate, dehydrated in a series of
lcohol and propylene oxide, infiltrated, and embedded in EPON
12. Thin sections were stained with uranyl acetate and lead citrate
rior to examination with a Philips 208S electron microscope.
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